Video
Advice to physicians on implementing immunotherapy in their practice
Author(s):
Video Player is loading.
In this video, Susan F. Slovin, MD, PhD, discusses considerations that physicians should know when they are beginning to implement immunotherapy in their practice, which are ideas associated with a presentation that she gave at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Slovin is a medical oncologist at the Memorial Sloan Kettering Cancer Center in New York City, New York.
Related Videos
Expert discusses the relationship between RCTs and real-world efficacy of prostate cancer treatments
Study data point to gender disparities in oncology research citations
Nitin Yerram, MD, highlights trial of 177Lu-PSMA-617 in localized prostate cancer
Neeraj Agarwal, MD, shares key takeaways from TALAPRO-2
Betty Wang, MD, recaps 3 key urologic cancer studies from EAU 2025
Neeraj Agarwal, MD, on the safety profile of talazoparib/enzalutamide in mCRPC
Rana McKay, MD, on persistence and adherence to relugolix for prostate cancer
Neeraj Agarwal, MD, on talazoparib/enzalutamide efficacy by HRR gene mutation status
Dr Louise Kostos on the rapidly evolving prostate cancer treatment landscape
An expert’s view on combination ARPI/ADT and long-term toxicity in prostate cancer
Related Content
